[go: up one dir, main page]

MX2021004566A - Compuestos terapeuticos. - Google Patents

Compuestos terapeuticos.

Info

Publication number
MX2021004566A
MX2021004566A MX2021004566A MX2021004566A MX2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A MX 2021004566 A MX2021004566 A MX 2021004566A
Authority
MX
Mexico
Prior art keywords
compounds
therapeutic compounds
relates
present
nrf2
Prior art date
Application number
MX2021004566A
Other languages
English (en)
Inventor
Fabien Jean Ghislain Roussel
Emma Louise Blaney
Barrie Phillip Martin
George Hynd
Duncan James Crick
Simon Ross Crumpler
Cathy Louise Lucas
Nick Charles Ray
Eileen Mary Seward
David Gareth Evans
Bozec Lucille Le
Thorsten Nowak
Michael Geoffrey Neil Russell
Siew Kuen Yeap
Sanjeet Singh Sehmi
Original Assignee
C4X Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1817193.4A external-priority patent/GB201817193D0/en
Priority claimed from GBGB1907674.4A external-priority patent/GB201907674D0/en
Application filed by C4X Discovery Ltd filed Critical C4X Discovery Ltd
Publication of MX2021004566A publication Critical patent/MX2021004566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos que son activadores de Nrf2. Los compuestos tienen la fórmula estructural I definida en la presente. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento de enfermedades o trastornos asociados con la activación de Nrf2.
MX2021004566A 2018-10-22 2019-10-22 Compuestos terapeuticos. MX2021004566A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1817193.4A GB201817193D0 (en) 2018-10-22 2018-10-22 Tetrahydroisoquinoline compounds
GBGB1907674.4A GB201907674D0 (en) 2019-05-30 2019-05-30 Tetrahydroisoquinoline compounds
PCT/GB2019/053012 WO2020084300A1 (en) 2018-10-22 2019-10-22 Therapeutic compounds

Publications (1)

Publication Number Publication Date
MX2021004566A true MX2021004566A (es) 2021-06-08

Family

ID=68393021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004566A MX2021004566A (es) 2018-10-22 2019-10-22 Compuestos terapeuticos.

Country Status (24)

Country Link
US (2) US12098148B2 (es)
EP (2) EP4252755A3 (es)
JP (2) JP7561742B2 (es)
KR (1) KR20210080474A (es)
CN (2) CN112996785B (es)
AU (1) AU2019364717B2 (es)
BR (1) BR112021007513A2 (es)
CA (1) CA3114859A1 (es)
DK (1) DK3870578T3 (es)
ES (1) ES2963613T3 (es)
FI (1) FI3870578T3 (es)
HR (1) HRP20231306T1 (es)
HU (1) HUE064111T2 (es)
IL (1) IL282330B2 (es)
LT (1) LT3870578T (es)
MX (1) MX2021004566A (es)
PH (1) PH12021550872A1 (es)
PL (1) PL3870578T3 (es)
PT (1) PT3870578T (es)
RS (1) RS64836B1 (es)
SG (1) SG11202103253YA (es)
SI (1) SI3870578T1 (es)
SM (1) SMT202300392T1 (es)
WO (1) WO2020084300A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4364804A3 (en) 2018-08-20 2024-09-04 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
JP7561742B2 (ja) 2018-10-22 2024-10-04 シーフォーエックス・ディスカバリー・リミテッド 治療用化合物
GB202005863D0 (en) * 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
GB202005852D0 (en) * 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
CN114507181B (zh) * 2020-11-17 2024-03-26 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
WO2023073364A1 (en) 2021-10-25 2023-05-04 C4X Discovery Limited Tetrahydroisoquinoline compounds that are keap1 binders
EP4446312A1 (en) * 2022-01-07 2024-10-16 Chugai Seiyaku Kabushiki Kaisha Nitrogen-containing heterocyclic compound having nrf2 activation effect

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68910999T2 (de) * 1988-02-19 1994-03-24 Smithkline Beecham Farma 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten.
KR890012970A (ko) 1988-02-23 1989-09-20 추후보충 테트라히드로 이소퀴놀린 유도체
US5389638A (en) 1993-09-10 1995-02-14 Abbott Laboratories Tetrahydroisoquinolines as alpha-2 antagonists and biogenic amine uptake inhibitors
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
ES2329739T3 (es) 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CN1731994A (zh) 2002-11-01 2006-02-08 武田药品工业株式会社 预防或治疗神经病的药剂
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
CA2707445A1 (en) 2007-11-30 2009-06-11 Biota Scientific Management Pty Ltd Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
WO2009105746A2 (en) 2008-02-22 2009-08-27 University Of South Florida Triazoles and processes for producing the same
BRPI0920237A2 (pt) 2008-10-21 2015-12-29 Metabolex Inc agonistas do receptor aril gpr120 e suas respectivas utilizações
US8367700B2 (en) 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
CN103450079B (zh) * 2013-08-14 2015-07-29 中国药科大学 四氢异喹啉羟基衍生物、其制备方法及其医药用途
WO2016149248A1 (en) 2015-03-15 2016-09-22 Emory University N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto
US20180179167A1 (en) 2015-06-15 2018-06-28 Glaxosmithkline Intellectual Property Development Limited Nrf2 REGULATORS
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
EP3645739A4 (en) 2017-06-28 2021-07-14 The Regents of the University of California METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
EP3781160A1 (en) 2018-04-20 2021-02-24 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease
EP3790872A1 (en) 2018-05-09 2021-03-17 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease
JP7561742B2 (ja) 2018-10-22 2024-10-04 シーフォーエックス・ディスカバリー・リミテッド 治療用化合物
US20220177466A1 (en) 2019-04-08 2022-06-09 Dana-Farber Cancer Institute, Inc. Degraders of kelch-like ech-associated protein 1 (keap1)
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
GB202005852D0 (en) * 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
GB202005863D0 (en) 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds

Also Published As

Publication number Publication date
EP4252755A3 (en) 2023-11-08
JP2024150460A (ja) 2024-10-23
EP3870578B1 (en) 2023-08-16
CN112996785B (zh) 2024-12-06
IL282330B1 (en) 2024-09-01
CN112996785A (zh) 2021-06-18
LT3870578T (lt) 2023-12-11
WO2020084300A1 (en) 2020-04-30
EP3870578A1 (en) 2021-09-01
US12098148B2 (en) 2024-09-24
US20250084075A1 (en) 2025-03-13
PH12021550872A1 (en) 2021-12-06
CA3114859A1 (en) 2020-04-30
JP7561742B2 (ja) 2024-10-04
ES2963613T3 (es) 2024-04-01
FI3870578T3 (fi) 2023-11-03
DK3870578T3 (da) 2023-11-13
RS64836B1 (sr) 2023-12-29
EP4252755A2 (en) 2023-10-04
SG11202103253YA (en) 2021-05-28
KR20210080474A (ko) 2021-06-30
CN119569706A (zh) 2025-03-07
IL282330B2 (en) 2025-01-01
PT3870578T (pt) 2023-11-15
BR112021007513A2 (pt) 2021-07-27
PL3870578T3 (pl) 2024-03-04
HRP20231306T1 (hr) 2024-02-02
US20220002286A1 (en) 2022-01-06
IL282330A (en) 2021-05-31
SMT202300392T1 (it) 2024-01-10
AU2019364717A1 (en) 2021-06-03
HUE064111T2 (hu) 2024-02-28
AU2019364717B2 (en) 2023-07-20
JP2022514437A (ja) 2022-02-10
SI3870578T1 (sl) 2024-02-29

Similar Documents

Publication Publication Date Title
PH12021550872A1 (en) Therapeutic compounds
MX2020001513A (es) Agentes de union a clec9a y su uso.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021009673A (es) Moduladores de ror-gamma.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
NZ783506A (en) Therapeutic compounds
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
PH12022552773A1 (en) Tetrahydroisoquinoline compounds as nrf2 activators
PH12022500021A1 (en) Il-17a modulators
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
PH12022553019A1 (en) Il-17a modulators
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12021550903A1 (en) Novel pyridazines
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
PH12022552775A1 (en) Tetrahydroisoquinoline compounds as nrf2 activators
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain